Brief: Viracta Therapeutics' Dan Chevallard Informed Co He Was Resigning From His Positions As CFO
March 21 (Reuters) - Viracta Therapeutics Inc VIRX.O :
* VIRACTA THERAPEUTICS - ON MARCH 15 DAN CHEVALLARD
INFORMED CO
HE WAS RESIGNING FROM HIS POSITIONS AS CFO, EFFECTIVE ON MARCH
20
* VIRACTA THERAPEUTICS - MELODY BURCAR WILL SERVE AS
COMPANY'S
INTERIM PRINCIPAL FINANCIAL OFFICER AND INTERIM PRINCIPAL
ACCOUNTING OFFICER
Source text for Eikon: ID:n0000950170-24-034230
Further company coverage: VIRX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Viracta Therapeutics
See all newsBrief: Viracta Therapeutics Announces Wind Down Of Operations
Brief: Viracta Therapeutics Announces Closure Of Naval-1 Clinical Trial And Exploration Of Strategic Alternatives
Brief: Viracta Therapeutics Receives Notice Of Non-Compliance From Nasdaq
Viracta Therapeutics Inc reports results for the quarter ended September 30 - Earnings Summary
Brief: Viracta Therapeutics Reports Q3 2024 Financial Results And Provides Business Update